NEW YORK (GenomeWeb) – Startup microbiome-based technology firm Enterome said today that it raised €10 million ($13.9 million) in the first tranche of a Series B financing round.

The Paris-based company said that the funding will be used to conduct R&D and business activities. Its technology platform, called the Metagenotyping system, is for developing new tools, such as biomarkers and companion diagnostics, for managing diseases. Eventually, the platform will be used for developing therapeutics for inflammatory bowel and metabolic disorders.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.